[
  {
    "title": "基于中国诊疗现状的《NCCN 指南：原发性皮肤淋巴瘤（2024 年第 1 版）》解读",
    "level": 1,
    "position": 1,
    "children": [],
    "link": "#nccn-2024-1"
  },
  {
    "title": "Interpretation of NCCN Clinical Practice Guidelines for Primary Cutaneous Lymphomas (Version 1. 2024) Based on the Current Diagnosis and Treatment Status of China",
    "level": 1,
    "position": 563,
    "children": [
      {
        "title": "1 原发性皮肤T细胞淋巴瘤",
        "level": 2,
        "position": 2330,
        "children": [
          {
            "title": "1.1 MF/SS",
            "level": 3,
            "position": 2348,
            "children": [
              {
                "title": "1.1.1 诊断",
                "level": 4,
                "position": 2492,
                "children": [],
                "link": "#111"
              },
              {
                "title": "1.1.2 辅助检查",
                "level": 4,
                "position": 2947,
                "children": [],
                "link": "#112"
              },
              {
                "title": "1.1.3 分期",
                "level": 4,
                "position": 3315,
                "children": [],
                "link": "#113"
              },
              {
                "title": "1.1.4 治疗",
                "level": 4,
                "position": 4776,
                "children": [],
                "link": "#114"
              },
              {
                "title": "1.1.4.1 治疗原则",
                "level": 4,
                "position": 4791,
                "children": [],
                "link": "#1141"
              }
            ],
            "link": "#11-mfss"
          }
        ],
        "link": "#1-t"
      },
      {
        "title": "(2)ⅠB～ⅡA期",
        "level": 2,
        "position": 5283,
        "children": [],
        "link": "#2ba"
      },
      {
        "title": "（3）ⅡB期",
        "level": 2,
        "position": 6070,
        "children": [],
        "link": "#3b"
      },
      {
        "title": "（4）Ⅲ期",
        "level": 2,
        "position": 6338,
        "children": [],
        "link": "#4"
      },
      {
        "title": "（5）SSⅣA1期或ⅣA2期",
        "level": 2,
        "position": 6556,
        "children": [],
        "link": "#5ssa1a2"
      },
      {
        "title": "（6）非SSⅣA2期和ⅣB期",
        "level": 2,
        "position": 6735,
        "children": [],
        "link": "#6ssa2b"
      },
      {
        "title": "（7）MF伴大细胞转化",
        "level": 2,
        "position": 6891,
        "children": [],
        "link": "#7mf"
      },
      {
        "title": "（8）复发难治性MF",
        "level": 2,
        "position": 7034,
        "children": [],
        "link": "#8mf"
      },
      {
        "title": "1.2 原发性皮肤CD30⁺T细胞淋巴增殖性疾病",
        "level": 2,
        "position": 7173,
        "children": [],
        "link": "#12-cd30t"
      },
      {
        "title": "1.2.1 概述",
        "level": 2,
        "position": 7362,
        "children": [],
        "link": "#121"
      },
      {
        "title": "2.4 治疗",
        "level": 2,
        "position": 8201,
        "children": [],
        "link": "#24"
      },
      {
        "title": "3 小结",
        "level": 2,
        "position": 8726,
        "children": [],
        "link": "#3"
      },
      {
        "title": "参考文献",
        "level": 2,
        "position": 9145,
        "children": [],
        "link": "#"
      }
    ],
    "link": "#interpretation-of-nccn-clinical-practice-guidelines-for-primary-cutaneous-lymphomas-version-1-2024-based-on-the-current-diagnosis-and-treatment-status-of-china"
  }
]